Entries by Trethera

Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis

7th January 2021 in /by

Los Angeles, January 7, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status (ODS) to TRE-515, Trethera’s first-in-class drug for the treatment of acute disseminated encephalomyelitis (ADEM). […]

Globally Renowned Research Scientist Dr. Michael Shepard Joins Trethera’s Scientific Advisory Board

8th December 2020 in /by

Los Angeles, December 8, 2020— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, is pleased to announce that distinguished researcher Michael Shepard, PhD has joined Trethera’s Scientific Advisory Board. Dr. Shepard is a recipient of numerous biotechnology patents and scientific awards […]

Trethera Announces U.S. Patent Application Filed for TRE-515, Extending Major Markets Exclusivity until 2041

2nd November 2020 in /by

Los Angeles, November 2, 2020— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases is pleased to announce that it has filed a provisional patent application with the US Patent & Trademark Office for the company’s first-in-class drug TRE-515.  If granted, […]